Introduction {#s1}
============

Mongolian medicines, which are being used for decades to manage various diseases ([@B48]), have a history of more than 1,000 years, and Mongolians have developed their system of medicines based on their own culture and experience ([@B22]). Treatment of diseases with Mongolian medicine-derived compounds seems to be highly attractive because of their accessibility and ease of isolation ([@B48]). Thus, Mongolian medicine is considered important in drug discovery. Furthermore, it has gradually gained interest as a valuable source of potential medicines.

*Cymbaria daurica* L. ([**Figure 1**](#f1){ref-type="fig"}) belongs to the family Scrophulariaceae and is an important component of Mongolian medicines ([@B47]). According to the *Mengyaozhengdian*, a complete and systematic Mongolian pharmaceutical classic of the 19th century, the whole plant is widely used in traditional Mongolian medicines for impetigo, psoriasis, pruritus, fetotoxicity, and diabetes ([@B18]; [@B36]; [@B47]; [@B6]). In addition, *C. daurica* has anti-inflammatory, anti-bacterial, and anti-oxidant activities ([@B47]; [@B19]). *C. daurica* has been extensively used in several classic herbal formulations recommended for anti-inflammation, such as *Siweixinbasan* and *Baweixinbasan* ([@B47]; [@B28]). Some researchers have explored the pharmacological activities of *C. daurica*. The anti-inflammatory activities of *C. daurica* ethanol extracts have been reported in xylene-induced ear edema KM mice and egg white-induced paw edema SD rats. These studies revealed that *C. daurica* ethanol extract could restrain ear edema in mice and paw edema in rats at 6 h after egg white-induced inflammation ([@B14]). [@B6] showed that the water and n-butanol extracts of *C. daurica* significantly reduced glucose levels in alloxan-induced diabetic mice. However, there are only a few phytopharmacological studies on *C. daurica*. The main pharmacological activities of *C. daurica* can be attributed to the different bioactive compounds previously reported in this traditional plant ([@B1]). However, the chemical composition of *C. daurica* is not entirely clear ([@B23]).

![Images of *Cymbaria daurica* from aerial parts of *C. daurica* **(A)** and the whole plant of *C. daurica* **(B)**.](fphar-11-00048-g001){#f1}

Therefore, to validate the therapeutic effects of *C. daurica*, we investigated the anti-inflammatory and α-glucosidase-inhibitory activities of various extracts (water extract, n-butanol extract, ethyl acetate extract, and petroleum ether extract) of *C. daurica* to identify the active extracts. Next, the compounds were separated from the active extracts. Combined with the results of previous phytochemical research ([@B23]; [@B3]), a database of *C. daurica* compounds was constructed; the chemical composition of the extracts was analyzed by UHPLC-Q-Exactive. In addition, the components with a high content and potential activity in *C. daurica* were simultaneously determined using a novel high-performance liquid chromatography (HPLC) method.

Materials and Methods {#s2}
=====================

Materials {#s2_1}
---------

### Plant Material {#s2_1_1}

*C. daurica* was collected in grassland (44°34′5.8″ N, 117°35′6.7″ E, Elevation: 1058.9 m), Haoletugaole Town, West Ujimqin Banner, XilinGol League, Inner Mongolia Autonomous Region in June 2018 and was authenticated by Life Science Faculty, Inner Mongolia University. Furthermore, voucher specimen of the same was deposited in the Herbarium of HIMC (Specimen No.: 152500180629025LY) for future reference.

### Cells and Reagents {#s2_1_2}

Raw 264.7 cell line was purchased from the Cell Bank in the China Academy of Science (Shanghai, China). High glucose Dulbecco's modified Eagle medium (DMEM) (Gibco, USA), fetal bovine serum (FBS), penicillin and streptomycin (HyClone, Thermo Scientific), phosphate-buffered saline (PBS), dimethyl sulfoxide (DMSO), lipopolysaccharide (Sigma, USA), and indomethacin (TMstandard, USA) were purchased from Sino-American Biotechnology Company (Beijing, China); ultrapure water was obtained from Gen Pure (Thermo, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were purchased from Sangon Biotech (Shanghai, China). The Nitric Oxide (NO) Assay kit was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). *p*-Nitrophenol α-D-glycopyranoside (pNPG) and α-glucosidase (EC 3.2.20, from *Saccharomyces cerevisiae*, lyophilized powder) were obtained from Sigma (USA).

### Chemicals and Reagents {#s2_1_3}

Acetonitrile (HPLC grade) was purchased from Fisher Scientific (Fisher Scientific, USA). Purified water was obtained using a Milli-Q system (Millipore, USA). All other reagents were of analytical grade. The reference compounds of 18 analytes were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China).

Methods {#s2_2}
-------

### Extraction and Processing {#s2_2_1}

Dried whole-plant powder of *C. daurica* (1.45 kg) was extracted successively with 70% ethanol to produce 362.5 g of extract. The extract was dissolved in water, and then extracted successively with petroleum ether, ethyl acetate, and n-butanol to produce 55.91, 21.47, and 110.77 g of dry extract, respectively. The aqueous phase contained 174.26 g of the residue.

### Anti-Inflammatory Assay {#s2_2_2}

#### Cell Culture {#s2_2_2_1}

RAW 264.7 mouse macrophages were cultured in high glucose DMEM supplemented with 10% FBS and a mixture of penicillin and streptomycin. The cells were maintained in a humidified incubator with an atmosphere of 5% CO~2~ at 37°C.

#### Cell Viability Assay {#s2_2_2_2}

The MTT assay was used to assess whether *C. daurica* extracts exerted cytoprotective effects on RAW 264.7 cells. RAW 264.7 cells were seeded in a 96-well plate at a density of 1 × 10^5^ cells/mL, cultured for 24 h, and then divided into control and treatment groups. The four extracts of *C. daurica* were dissolved in DMSO (\<0.01%) and diluted with complete culture medium. The treatment cell groups were pretreated with vehicle alone or with different concentrations (25, 50, 100, 200, 400, 800, 1,600, and 3,200 μg/mL) of *C. daurica* extracts (water, n-butanol, ethyl acetate, and petroleum-ether extracts) for 24 h. The cells were then incubated with 10 µL of MTT solution for 4 h at 37°C, after which the supernatant was discarded and 150 µL of DMSO was added to each well. The plates were oscillated at a low speed for 5 min at room temperature until all the formed crystals were fully dissolved. Optical density was determined at an absorbance wavelength of 570 nm (Thermo Scientific Multiskan FC, Thermo, USA). The optical density of the control (untreated) cells was designated as 100% viability.

#### Nitric Oxide Assay {#s2_2_2_3}

RAW 264.7 cells were plated at a density of 5 × 10^5^ cells/mL in 24-well plates, cultured for 12 h, and then treated with LPS (1 μg/mL) and incubated for 4 h. Thereafter, the cells were treated with different concentrations (25, 50, 100, 200, and 400 μg/mL) of *C. daurica* extracts (water, n-butanol, ethyl acetate, and petroleum-ether extracts) and incubated for an additional 20 h. Meanwhile, the negative control groups were treated for 20 h with 400 μg/mL of each extract, but not with LPS. Indomethacin (6.25, 12.5, 25, 50, and 100 μM) was used as the positive control ([@B8]). The amount of NO in the medium was detected using the Griess test. One hundred microliters of each supernatant were mixed with equal volume of Griess reagent (1% sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine dihydrochloride in water). The absorbance of the mixture at 550 nm and concentration of nitrite were determined using serially diluted sodium nitrite as the standard ([@B37]).

### α-Glucosidase Inhibition Assay {#s2_2_3}

We examined whether the four *C. daurica* extracts could inhibit the activity of α-glucosidase using a previously published method ([@B38]). Briefly, each extract of *C. daurica* was dissolved in DMSO (\< 0.05%), and then diluted with phosphate buffer (pH 6.9). Then, 20 µL of each extract (at a concentration of 50, 75, 100, 125, or 150 μg/mL) was added into a 96-well microplate. Next, 10 µL of α-glucosidase from *Saccharomyces*, 10 µL of 3 µM glutathione, and 20 μL of phosphate buffer were added to each well, and the plate was incubated at 37°C for 10 min. Thereafter, 20 μL of 0.01 M p-nitrophenyl glucopyranoside (pNPG) was added to each well to quench the reaction, and the plate was incubated at 37°C for 20 min. The reaction was stopped by the addition of 100 µL of 0.1 M Na~2~CO~3~ into each well, and the absorbance was recorded at 405 nm. The control sample contained buffer instead of α-glucosidase. Acarbose was used as the positive control.

### Isolation of Pure Compounds {#s2_2_4}

The n-butanol extract (25 g) was fractionated on a D101 macroporous resin column using EtOH--H~2~O (70:30) to obtain 15 fractions, and then by TLC to obtain four main fractions (Frs. A1--A4). Fr. A1 was recrystallized repeatedly (MeOH--EtOH) to obtain compound 1 (57.9 mg). Fr. A2 was further purified *via* repeated chromatography on Sephadex LH-20 to obtain compound 2 (11.3 mg). Fr. A3 was further purified by chromatography on an ODS column (MeOH--H~2~O, 0:100--20:80) to obtain four fractions (Frs. B1--B4). Fr. B1 was further purified by repeated chromatography on silica gel to obtain compound 3 (25.4 mg). Fr. B2 was further purified by chromatography on an MCI column (MeOH--H~2~O, gradient elution) to obtain compound 4 (14.0 mg). Fr. B3 was further purified by repeated chromatography on Sephadex LH-20 to obtain compound 5 (16.6 mg). Fr. B4 was further purified by repeated chromatography on Sephadex LH-20 to obtain compound 6 (27.0 mg). Fr. A4 was further purified by chromatography on an ODS column (MeOH--H~2~O (30:70--70:30) to obtain seven fractions (Frs. C1--C7). Combined Fr. C4 was further purified by repeated chromatography on Sephadex LH-20 (MeOH--H~2~O, 70:30) to obtain compounds 7 (119.9 mg) and 8 (19.8 mg).

Ethyl acetate extract (17 g) was fractionated on a D101 macroporous resin column using EtOH--H~2~O (70:30) to obtain 10 main fractions (Frs. D1--D10) \[10\]. Frs. D4--D7 was further purified by chromatography on an ODS column (MeOH--H~2~O, 30:70--70:30) to obtain seven fractions (Frs. E1--E7). Combined Fr. E4 was further purified by repeated chromatography on Sephadex LH-20 (MeOH--H~2~O, 70:30) to obtain compounds 7 (74.0 mg) and 8 (22.0 mg). Frs. D8--D9 was further purified by chromatography on silica gel (CHCl~3~--MeOH, 90:10--60:40) to obtain 12 fractions (Frs. F1--12). Combined Frs. F2--F6 was further purified by repeated chromatography on Sephadex LH-20 (MeOH--H~2~O, 80:20) to obtain compounds 9 (20.4 mg) and 10 (23.7 mg).

### HPLC-MS {#s2_2_5}

#### HPLC--MS/MS System and Operating Conditions {#s2_2_5_1}

The Thermo Scientific™ Ultimate™ 3000 RS system was used in this assay. Chromatographic separation was performed on the Hypersil GOLD C~18~ (100 mm × 2.1 mm, 3 μm; Thermo Scientific) column. Acetonitrile (solvent B) and water (containing 0.1% formic acid, solvent A) were used as the mobile phase. The gradient was as follows: 0--35 min, 5%--60% B. The flow rate was 0.3 mL/min.

Mass spectrometry data were acquired using the Q Exactive High-Resolution Benchtop Quadrupole Orbitrap Mass Spectrometer (Thermo Fisher Scientific, USA) equipped with an ESI interface in the positive and negative ion modes. Optimal parameters were as follows: probe heater temperature, 350°C; spray voltage, 3.5 kV for the positive and negative ion modes; sheath gas, 35 arb; auxiliary gas, 10 arb. Capillary temperature was set at 320°C and S-lens was 50 V. Full-scan MS data were generated across a mass range of 100--1500 Da. The stepped normalized collision energy setting was 20, 40, and 60 eV. All MS spectra were acquired using the Q Exactive Mass Spectrometer controlled using Xcalibur 3.0 software (Thermo Fisher Scientific).

#### Data Processing {#s2_2_5_2}

MS data were processed using QualBrowser of Xcalibur 3.0 software (Thermo Fisher Scientific), and they included extracted ion chromatograms, fragmentation behavior, and elemental compositions with mass errors within 5 ppm. All analytes were identified using their elemental composition, accurate mass measurement, elution order, fragmentation behavior, fragmentation pattern of the standard compound, and comparison with reliable data in compounds database ([@B43]).

### HPLC Analysis {#s2_2_6}

The nucleosil C18 column (4.6 mm × 250 mm, 5 μm; Agilent) was used for the analysis of catalpol, verbascoside, isoacteoside, luteolin, and apigenin by HPLC. The mobile phase consisted of water (containing 0.1% phosphoric acid, solvent A) and acetonitrile (solvent B). The gradient was as follows: 0--15 min, 1% B; 15--25 min, 1--15% B; 25--70 min, 15--35% B; 70--75 min, 35--50% B. The flow rate was 1 mL/min. Injection volume was 10 μL, and the temperature of the column was maintained constant at 30°C. Detection was performed using at wavelengths of 210, 330, and 365 nm. The n-butanol and ethyl acetate extracts of *C. daurica* were analyzed by HPLC. Each sample was assayed in triplicate. Chromatographic peaks of the samples were quantified *via* external standard method. The HPLC method developed in this study was validated for linearity, precision, repeatability, and stability.

### Statistical Analysis {#s2_2_7}

All data were analyzed using SPSS 19.0, and the results are presented as mean ± standard deviation (SD) of three independent experiments. Values with *p* \< 0.05 were considered significantly different.

Results {#s3}
=======

Anti-Inflammatory Assay {#s3_1}
-----------------------

### Effect of the Four *C. daurica* Extracts on the Viability of RAW 264.7 Cells {#s3_1_1}

RAW 264.7 cells, pretreated for 24 h with five different concentrations (25, 50, 100, 200, and 400 μg/mL) of the water, n-butanol, ethyl acetate, and petroleum-ether extracts showed no significant differences in cell viability compared with that of the control group (*p* \> 0.05) ([**Figure 2**](#f2){ref-type="fig"}). However, pretreatment with 800, 1,600, or 3,200 μg/mL of the water, n-butanol, ethyl acetate, or petroleum-ether extract significantly decreased cell activity (*p* \< 0.01). These results indicate that pretreatment of RAW 264.7 cells with the four *C. daurica* extracts at concentrations of 25, 50, 100, 200, and 400 μg/mL did not result in cytotoxicity; therefore, these concentrations were selected for further experiments.

![Effect of the four *C. daurica* extracts on viability of RAW 264.7 cells. **(A)** water extract. **(B)** n-butanol extract. **(C)** ethyl acetate extract. **(D)** petroleum ether extract. Data are presented as means ± SD, *n* = 5. \*\**p* \< 0.01, \*\*\**p* \< 0.001 compared with control.](fphar-11-00048-g002){#f2}

### Effect of Extracts From Four Parts of *C. daurica* on RAW 264.7 Cell NO Production {#s3_1_2}

As shown in [**Figure 3**](#f3){ref-type="fig"}, RAW 264.7 cells did not release NO in response to the culture medium. In this study, LPS was used to activate RAW 264.7 cells. NO production by RAW 264.7 cells stimulated with LPS (1 μg/mL) was significantly increased compared with that of the control group (*p* \> 0.001). When used separately, the four extracts of *C. daurica* (400 μg/mL) did not affect NO production in RAW 264.7 cells (*p* \> 0.05). However, when different concentrations of n-butanol and ethyl acetate extracts (25, 50, 100, 200, and 400 μg/mL) were added to the culture media during cell stimulation (20 h), NO production was inhibited in a dose-dependent manner (*p* \< 0.05, [**Figures 3B, C**](#f3){ref-type="fig"}). The n-butanol and ethyl acetate extracts exhibited significant anti-inflammatory activity with the IC~50~ values of 197.00 ± 0.74 and 90.00 ± 1.05 μg/mL, respectively, whereas, indomethacin, as the positive control, had an IC~50~ of 59.97 ± 0.80 µM ([**Table 1**](#T1){ref-type="table"}). However, the water and petroleum-ether extracts did not inhibit LPS-induced NO production and did not exhibit anti-inflammatory activity ([**Figures 3A, D**](#f3){ref-type="fig"}). These results suggest that the extracts of *C. daurica* may function, at least partially, *via* macrophage activation in the host defense response.

![Effect of extracts from four parts of the *C. daurica* on LPS-induced NO production in RAW 264.7 cell. **(A)** water extract. **(B)** n-butanol extract. **(C)** ethyl acetate extract. **(D)** petroleum ether extract. **(E)** indomethacin. Data are presented as means ± SD, *n* = 5. \*\*\**p* \< 0.001 compared with control; ^\#\#\#^ *p* \< 0.001, ^\#\#^ *p* \< 0.01, ^\#^ *p* \< 0.05 compared with LPS. (Control group; Model group: LPS; Negative control group: water extract, n-butanol extract, ethyl acetate extract, petroleum ether extract; Treated group: water extract + LPS, n-butanol extract + LPS, ethyl acetate extract + LPS, petroleum ether extract + LPS).](fphar-11-00048-g003){#f3}

###### 

IC~50~ values (µg/mL) of inhibitory activities of *C. daurica* extracts on LPS-induced NO production in RAW264.7 cell. (n = 5,x ± s).

  Source                                            Extract fractions   IC~50~
  ------------------------------------------------- ------------------- -------------------------------------------------
  *C. daurica*                                      Water extract       --
  n-butanol extract                                 197.00 ± 0.74       
  Ethyl acetate extract                             90.00 ± 1.05        
  Petroleum ether extract                           --                  
  Indomethacin[^a^](#fnT1_1){ref-type="table-fn"}   --                  59.97 ± 0.80[^b^](#fnT1_2){ref-type="table-fn"}

Indomethacin was used as positive control.

The concentration units were μM.

α-Glucosidase Inhibition {#s3_2}
------------------------

To the best of our knowledge, this is the first study to report that the extracts of *C. daurica* can inhibit the activity of α-glucosidase. The results of the effects of *C. daurica* extracts on α-glucosidase activity are presented in [**Table 2**](#T2){ref-type="table"}. As shown in [**Table 2**](#T2){ref-type="table"}, the water, n-butanol, ethyl acetate, and petroleum-ether extracts of *C. daurica* exerted inhibitory activity on the activity of α-glucosidase (IC~50~ = 175.8 ± 2.11, 133.2 ± 2.59, 105.9 ± 0.89, and 173.6 ± 1.11 µg/mL, respectively). Among the four extracts of *C. daurica*, ethyl acetate extract exerted significant inhibitory effects on α-glucosidase, showing an IC~50~ of 105.9 ± 0.89 μg/mL; the α-glucosidase-inhibition potency was equivalent to that of acarbose (108.2 ± 1.28 μg/mL, *p* \> 0.05). These results show that *C. daurica* extracts can be used to design new plant-based drugs and nutraceuticals.

###### 

IC~50~ values (µg/mL) of α-glucosidase inhibition activity of *C. daurica* extracts. (n = 3,x ± s).

  Source                    Extract fractions   IC~50~
  ------------------------- ------------------- --------------
  *C. daurica*              Water extract       175.8 ± 2.11
  n-butanol extract         133.2 ± 2.59        
  Ethyl acetate extract     105.9 ± 0.89        
  Petroleum ether extract   173.6 ± 1.11        
  Acarbose                  --                  108.2 ± 1.28

Isolation of Pure Compounds {#s3_3}
---------------------------

The n-butanol and ethyl acetate extracts showed considerable anti-inflammatory and α-glucosidase-inhibitory activities. Furthermore, we conducted phytochemical analysis of the n-butanol and ethyl acetate extracts from *C. daurica*. We isolated compounds 1, 2, 3, 4, 5, 6, 7, and 8 from the n-butanol extract. Compounds 7, 8, 9, and 10 were isolated from the ethyl acetate extract. The structure of these compounds was identified by comparing their spectral data (obtained *via* proton nuclear magnetic resonance \[^1^H-NMR, ^13^C-NMR\] (the spectral data of compounds 1--10 are shown in [**Supplemental Material**](#SM1){ref-type="supplementary-material"}), and electrospray ionization \[ESI-MS\]) with published data on catalpol (1) ([@B33]), vanillic acid (2) ([@B7]), ajugol (3) ([@B49]), cistanoside F (4) ([@B30]), echinacoside (5) ([@B52]), arenarioside (6) ([@B2]), verbascoside (7) ([@B44]), isoacteoside (8) ([@B29]), apigenin (9) ([@B10]), and tricin (10) ([@B15]). The chemical structure of the 10 compounds is shown in [**Figure 4**](#f4){ref-type="fig"}. Our study is the first to isolate compounds 2, 4, 5, 6, 7, 8, and 10 from *C. daurica*. Furthermore, this is the also first report of phenylethanoloside compounds found in *C. daurica*.

![The chemical structures of ten monomeric compounds. 1 catalpol; 2 vanillic acid; 3 ajugol; 4 cistanoside F; 5 echinacoside; 6 arenarioside; 7 verbascoside; 8 isoacteoside; 9 apigenin; 10 tricin.](fphar-11-00048-g004){#f4}

HPLC-MS Analysis {#s3_4}
----------------

We examined the chemical composition of *C. daurica*. Chemical composition of the n-butanol and ethyl acetate extracts of *C. daurica* was determined by UHPLC-Q-Exactive. To determine the chemical composition, we evaluated the retention time, ionic species, and major fragments in MS and MS^2^ spectra. We also searched an online database and literature, and examined fragmentation patterns of standard compounds. Based on these analyses, the chemical structure of the n-butanol and ethyl acetate extracts of *C. daurica* was tentatively identified and classified into four major groups, namely, phenylethanoid glycosides, flavonoids, iridoids, and phenolic acids. The total ion chromatograms of n-butanol and ethyl acetate extracts of *C. daurica*, both in the negative ion mode, are presented in [**Figure 5**](#f5){ref-type="fig"}. Retention time, molecular formula, theoretical mass, and measured mass of the 30 identified compounds are presented in [**Table 3**](#T3){ref-type="table"}.

![The total ion chromatograms (TIC) of n-butanol extract **(A)** and ethyl acetate extract **(B)** form the *C. daurica* in negative mode.](fphar-11-00048-g005){#f5}

###### 

Identification of major chemical constituents in n-butanol extract and ethyl acetate extract form the *C. daurica*.

  Peak   Compounds                              Formula           Ion mode   Theoretical (*m/z*)   n-butanol extract   Ethyl acetate extract           
  ------ -------------------------------------- ----------------- ---------- --------------------- ------------------- ----------------------- ------- -----------
  1      Catalpol\*                             C~15~H~22~O~10~   Negative   361.11402             2.15                361.11423               2.00    361.11420
  2      Isoxepac glucuronide                   C~22~H~20~O~10~   Negative   443.09837             2.58                443.09638               2.56    443.24743
  3      Aucubin\*                              C~15~H~22~O~9~    Negative   345.11910             3.48                345.11911               --      --
  4      Vanillic acid\*                        C~8~H~8~O~4~      Negative   167.03498             4.29                167.03422               --      --
  5      Ajugol\*                               C~15~H~24~O~9~    Negative   347.13475             4.72                347.13461               --      --
  6      Loganic acid\*                         C~16~H~24~O~10~   Negative   375.12967             5.37                375.12974               5.37    375.12992
  7      1β-methoxylgardendiol                  C~10~H~14~O~5~    Negative   213.07684             5.73                213.07636               --      --
  8      Cistanoside F\*                        C~21~H~28~O~13~   Negative   487.14571             6.02                487.30565               5.94    487.07273
  9      Gentiopicroside                        C~16~H~20~O~9~    Negative   355.10345             6.39                355.10373               --      --
  10     Caffeic acid\*                         C~9~H~8~O~4~      Negative   179.03498             7.19                179.03583               7.13    179.03406
  11     1β-hydroxyl-4-epigardendiol            C~11~H~16~O~5~    Negative   227.09249             8.24                227.07684               --      --
  12     Campneoside II                         C~29~H~36~O~16~   Negative   639.19305             9.89                639.19274               9.88    639.19316
  13     Echinacoside\*                         C~35~H~46~O~20~   Negative   785.25096             10.16               785.25056               10.17   785.25104
  14     Rutin\*                                C~27~H~30~O~16~   Negative   609.14610             11.20               609.14640               --      --
  15     Arenarioside\*                         C~34~H~44~O~19~   Negative   755.24040             11.49               755.23968               11.48   755.24013
  16     Cynaroside\*                           C~21~H~20~O~11~   Negative   447.09328             11.75               447.09342               11.76   447.12989
  17     Rehmapicroside                         C~16~H~26~O~8~    Negative   345.15549             --                  --                      11.84   345.15567
  18     Verbascoside\*                         C~29~H~36~O~15~   Negative   623.19814             12.14               623.19793               12.12   623.19875
  19     4-Coumaric acid\*                      C~9~H~8~O~3~      Negative   165.05462             12.37               165.05488               12.35   165.11338
  20     Isoacteoside\*                         C~29~H~36~O~15~   Negative   623.19814             12.83               623.19793               12.91   623.19875
  21     Apigenin-7-*O*-*β*-D-glucuronide       C~21~H~20~O~10~   Negative   431.09837             13.3                431.19252               13.27   431.09855
  22     Tricin-7-*O*-*β*-D-glucuronide         C~23~H~24~O~12~   Negative   491.11949             13.76               491.15596               13.78   491.19275
  23     Cistanoside C                          C~30~H~38~O~15~   Negative   637.21379             13.83               637.10461               13.85   637.21399
  24     Chrysoeriol-7-*O*-*β*-D--glucuronide   C~22~H~22~O~11~   Negative   461.10893             14.40               461.16673               14.32   461.14572
  25     Jionoside C                            C~29~H~36~O~13~   Negative   591.20831             14.69               591.07978               14.68   591.26153
  26     Martynoside                            C~31~H~40~O~15~   Negative   651.22944             16.02               651.19323               16.03   651.19342
  27     Luteolin\*                             C~15~H~10~O~6~    Negative   285.04046             --                  --                      16.64   285.04056
  28     Apigenin\*                             C~15~H~10~O~5~    Negative   269.04554             18.94               269.04461               18.93   269.04565
  29     Tricin\*                               C~17~H~14~O~7~    Negative   329.06667             19.45               329.08803               19.44   329.23330
  30     Chrysoeriol\*                          C~16~H~12~O~6~    Negative   299.05611             19.55               299.07734               19.54   299.05626

\* Compared with standard compounds.

Individual compounds in the n-butanol and ethyl acetate extracts of *C. daurica* were characterized as follows. Peak 1 in the n-butanol and ethyl acetate extracts was observed at *m/z* 361. According to [@B40], peak 1 was characterized as catalpol, consistent with the fragmentation pattern of the standard compound. Based on MS, MS/MS data, data found in the literature ([@B40]), and comparison with fragmentation patterns of the standard compounds, vanillic acid (peak 4) was detected in the n-butanol extract of *C. daurica*. Vanillic acid showed fragments at *m/z* 167, 151, and 107. Peak 18, at *m/z* 623, was identified as verbascoside because it showed fragments at *m/z* 461 and 161. This fragmentation pattern was consistent with that of the standard compound, as well as patterns reported in previous studies ([@B40]; [@B50]). Peak 20 also showed similar fragmentation pattern and was proposed to be a verbascoside isomer. Based on comparison with fragmentation pattern of the standard compound, Peak 20 was identified as isoacteoside. Peak 29, with *m/z* 329, was proposed to be tricin and showed fragments of *m/z* 314, 162, and 151 in the MS/MS spectrum. These MS^2^ data matched the fragmentation pattern of the standard compound.

Aucubin, caffeic acid, rutin, cynaroside, catalpol echinacoside, and apigenin, previously reported as present in *C. daurica*, show strong anti-inflammatory and hypoglycemic activities ([@B42]; [@B27]; [@B13]; [@B16]; [@B24]; [@B45]; [@B4]), whereas vanillic acid, luteolin, verbascoside, and tricin show considerable anti-inflammatory activity ([@B21]; [@B46]; [@B25]; [@B26]).

HPLC Analysis {#s3_5}
-------------

Based on the biological activity and chemical composition of the n-butanol and ethyl acetate extracts, identified by HPLC-MS, we developed a novel HPLC method for simultaneous identification of five compounds with high content and potential activity. A sample chromatogram is shown in [**Figure 6**](#f6){ref-type="fig"}. As illustrated in [**Figure 6**](#f6){ref-type="fig"}, the five compounds were well separated under the described chromatographic conditions. As shown in [**Table 4**](#T4){ref-type="table"}, all calibration curves exhibited excellent linearity (R^2^ = 0.9991--0.9998) in a relatively wide concentration range. This method was validated for precision, repeatability, and stability, as shown in [**Table 5**](#T5){ref-type="table"}. These results show that the HPLC method, developed in this study, was precise, accurate, and sensitive enough for simultaneous quantitative evaluation of five compounds in *C. daurica*. This novel HPLC method was subsequently used for simultaneous identification of five compounds in the n-butanol and ethyl acetate extracts of *C. daurica*. As shown in [**Table 6**](#T6){ref-type="table"}, the content of each compound varied depending on the extract; for example, the content of verbascoside in the n-butanol extract and that in ethyl acetate extract was 114.263 ± 0.255 and 162.955 ± 0.203 mg/g, respectively.

![The fingerprints of the five compounds in different extracts of *C. daurica*. **(A)** Mixed standard. **(B)** n-butanol extract. **(C)** ethyl acetate extract. 1 catalpol; 2 verbascoside; 3 isoacteoside; 4 luteolin; 5 apigenin.](fphar-11-00048-g006){#f6}

###### 

Calibration curve for five compounds.

  Compound       Calibration curve[^a^](#fnT4_1){ref-type="table-fn"}   R^2^     Linear range (µg/mL)
  -------------- ------------------------------------------------------ -------- ----------------------
  Catalpol       y = 45.201x + 0.6434                                   0.9997   0.472--2.832
  Verbascoside   y = 264.5x + 28.613                                    0.9991   0.346--2.076
  Isoacteoside   y = 636.89x + 0.5168                                   0.9998   0.022--0.132
  Luteolin       y = 1123.9x + 0.538                                    0.9995   0.028--0.168
  Apigenin       y = 1083.6x + 0.2633                                   0.9995   0.018--0.108

y = peak area and x = concentration (µg/mL).

###### 

Precision, repeatability, and stability of five compounds (RSD%, n = 5).

  ------------------------------------------------------------------------------------------------------------------------------
  Compound       Precision RSD   Repeatability RSD\    Repeatability RSD\        Stability RSD\        Stability RSD\
                                 (n-butanol extract)   (Ethyl acetate extract)   (n-butanol extract)   (Ethyl acetate extract)
  -------------- --------------- --------------------- ------------------------- --------------------- -------------------------
  Catalpol       0.09            0.31                  --                        1.71                  --

  Verbascoside   0.89            0.33                  1.32                      0.37                  0.84

  Isoacteoside   0.15            0.53                  1.35                      0.61                  0.48

  Luteolin       0.59            --                    0.97                      --                    1.02

  Apigenin       0.43            --                    1.93                      --                    1.12
  ------------------------------------------------------------------------------------------------------------------------------

###### 

Quantitative analytical results of n-butanol extract and ethyl acetate extract form the *C. daurica* (mg/g, n = 3,x ± s).

  Extract fractions       Catalpol          Verbascoside      Isoacteoside     Luteolin         Apigenin
  ----------------------- ----------------- ----------------- ---------------- ---------------- ----------------
  n-butanol extract       113.918 ± 0.127   114.263 ± 0.255   9.475 ± 0.059    --               --
  Ethyl acetate extract   --                162.955 ± 0.203   15.967 ± 0.021   27.701 ± 0.026   14.079 ± 0.004

Discussion {#s4}
==========

Recently, Mongolian medicines have been more commonly used, owing to their low adverse effect; they also protect against and treat certain diseases. Furthermore, research on approaches that help explore the therapeutic value of natural pharmacotherapeutic agents has become a growing trend ([@B9]). *C. daurica* is widely used in traditional Mongolian medicine for the treatment of impetigo, psoriasis, pruritus, fetotoxicity, and diabetes. In spite of its tremendous therapeutic potential, complete chemical signature of *C. daurica* is unknown. Therefore, the aim of this study was to assess bioactivity and analyze chemical composition of *C. daurica* to lay a foundation to identify new drugs.

Based on the traditional therapeutic effect of *C. daurica*, the anti-inflammatory and α-glucosidase-inhibitory activities of four polar *C. daurica* extracts were preliminarily evaluated to identify the active extracts. None of the tested samples exhibited cytotoxic effects at the effective concentrations ([**Figure 2**](#f2){ref-type="fig"}). The n-butanol and ethyl acetate extracts showed pronounced inhibitory effects on LPS-induced NO production in RAW 264.7 cells compared with that of indomethacin ([**Table 1**](#T1){ref-type="table"}). Furthermore, the four extracts of *C. daurica* (400 μg/mL) used separately did not affect NO production in RAW 264.7 cells (*p* \> 0.05) ([**Figure 3**](#f3){ref-type="fig"}). Activated macrophages release inflammatory mediators such as NO. The excessive production of inflammatory mediators in prolonged inflammation can cause cellular and tissue damage ([@B34]). NO overproduction leads to cellular responses including apoptosis and necrosis ([@B32]). To prevent the adverse effect of prolonged inflammation, anti-inflammatory agents are needed. Any substance that inhibits the production of these pro-inflammatory molecules is considered a potential anti-inflammatory agent ([@B12]). Thus, the active extracts of *C. daurica* were n-butanol and ethyl acetate extracts.

In this study, the ethyl acetate extract significantly inhibited α-glucosidase (with IC~50~ of 105.9 ± 0.89 μg/mL), and the α-glucosidase-inhibition potency was equivalent to that of acarbose (108.2 ± 1.28 μg/mL) ([**Table 2**](#T2){ref-type="table"}). n-Butanol presented the second highest inhibitory activity, with the IC~50~ value of 133.2 ± 2.59 μg/mL. The therapeutic action of *C. daurica* extracts can be attributed to their inhibition activity against α-glucosidase, thus reducing postprandial hyperglycemia and controlling diabetes. Acarbose is an inhibitor of carbohydrate digesting enzyme used to decrease glucose absorbance, but it has some gastrointestinal adverse effects ([@B11]). Mongolian medicines can inhibit carbohydrate-metabolizing enzymes; due to their almost no adverse effect, studies have focused on *C. daurica* extracts as new α-glucosidase natural inhibitors.

The separation and identification of n-butanol and ethyl acetate extracts from *C. daurica* yielded 10 compounds, namely, catalpol, vanillic acid, ajugol, cistanoside F, echinacoside, arenarioside, verbascoside, isoacteoside, apigenin, and tricin ([**Figure 4**](#f4){ref-type="fig"}). Among them, vanillic acid, cistanoside F, echinacoside, arenarioside, verbascoside, isoacteoside, and tricin were isolated in *C. daurica* for the first time. Previous phytochemical reports described that the main chemical constituents in *C. daurica* are flavonoids and iridoids ([@B23]; [@B3]). The present study demonstrated for the first time that *C. daurica* contains phenylethanoid glycosides. Based on these results, 30 compounds in n-butanol and ethyl acetate extracts of *C. daurica* were determined by UHPLC-Q-Exactive ([**Figure 5**](#f5){ref-type="fig"} and [**Table 3**](#T3){ref-type="table"}). The results further proved that the main chemical constituents in *C. daurica* included phenylethanoid glycosides, flavonoids, and iridoids. In addition, this novel HPLC method was subsequently used for the simultaneous identification of five compounds (catalpol, verbascoside, isoacteoside, luteolin, and apigenin) with high content and potential activity in the n-butanol and ethyl acetate extracts of *C. daurica* ([**Figure 6**](#f6){ref-type="fig"}, [**Table 4**](#T4){ref-type="table"}, and [**Table 5**](#T5){ref-type="table"}). It is worth noting that the content of verbascoside in the n-butanol and ethyl acetate extracts of *C. daurica* was very high, that is, 114.263 ± 0.255 and 162.955 ± 0.203 mg/g, respectively ([**Table 6**](#T6){ref-type="table"}). This study provided a chemical basis for the further development and utilization of *C. daurica*.

The anti-inflammatory and anti-diabetic activities of *C. daurica* can be attributed to the bioactive compounds. Phenylethanoid glycosides, flavonoids, and iridoids exhibit extensive pharmacological activities, including anti-inflammatory ([@B17]; [@B41]; [@B51]) and anti-diabetic activities ([@B31]; [@B39]). Verbascoside has been the subject of biological studies demonstrating anti-inflammatory activity in several models, such as the intestinal inflammation model, where it decreased the presence of pro-inflammatory molecules ([@B5]). Previous studies have shown that verbascoside downregulates some pro-inflammatory signal transduction pathways by increasing the activity of tyrosine phosphatase SHP-1 in U937 cell line ([@B35]). Furthermore, studies have reported that intravenous injection of catalpol exhibited anti-hyperglycemic activity in a dose-dependent manner in streptozotocin-induced diabetic rats representing insulin-dependent diabetes mellitus ([@B20]). Therefore, the development of anti-inflammatory and anti-diabetic drugs from *C. daurica* has considerable advantages. However, understanding the mechanisms underlying the anti-inflammatory and anti-diabetic activities of *C. daurica* needs more studies *in vitro* and *in vivo*. Further studies are also needed to identify the anti-inflammatory and anti-diabetic compounds, and to deeply comprehend the mechanism of action of the active compounds in n-butanol and ethyl acetate extracts of *C. daurica*.

In conclusion, the results of our study showed that phenylethanol-glycoside compounds are important components of *C. daurica*. These findings support the anti-inflammatory and anti-diabetic activities of *C. daurica* and indicate that *C. daurica* could be utilized as a potential source of novel anti-diabetic and anti-inflammatory agents.
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